Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) can cause excessive appetite suppression leading to restrictive eating behaviors, severe caloric restriction, dehydration, and acute kidney injury, particularly in unmonitored or high-risk populations.
If you are prescribed a GLP-1 agonist (like Ozempic or Mounjaro), do not use it without medical supervision. Ensure you are screened for eating disorders and receive dietary counseling. Watch for signs of extreme food aversion or dehydration, and stop the medication if you lose weight too rapidly or feel severe nausea/diarrhea, seeking immediate medical attention if you experience kidney issues.
These cases highlight the complexity of appetite regulation and the need for careful monitoring when using these medications... [Case 3] reported severe diarrhea and reported the loss of almost all sense of hunger and thirst, stopping nearly all liquid intake... Laboratory evaluation of renal function revealed their creatinine had increased from 0.6 to 3.6 mg/dL, prompting hospitalization for acute kidney injury and treatment for dehydration and electrolyte deficiencies.
Why this rating
Evidence is based on a series of four case reports and clinical opinion, not randomized controlled trials.
Source
Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss
Jesse Richards et al. · 2023
DOI 10.31234/osf.io/uxa78
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →